New Insights into Using Lipid Based Suspensions for 'Brick Dust' Molecules: Case Study of Nilotinib

dc.accessRightsAnonymous*
dc.audienceScienceen_US
dc.contributor.authorKoehl, Niklas
dc.contributor.authorKuentz, Martin
dc.date.accessioned2020-02-06T10:54:31Z
dc.date.available2020-02-06T10:54:31Z
dc.date.issued2019-02-22
dc.description.abstractPurposeLipid suspensions have been shown to be a suitablebio-enabling formulation approach for highly lipophilic or‘grease ball’drug molecules, but studies on‘brick dust’drugsare lacking. This study explored the utility of lipid suspensionsfor enhancing oral bioavailability of the rather hydrophobicdrug nilotinibin vivoin rats.MethodsFour lipid suspensions were developed containinglong chain triglycerides, medium chain triglyceride, longchain monoglycerides and medium chain monoglyceridesandin vivobioavailability was compared to an aqueous suspen-sion. Additionally,in vitrolipolysis and wettability tests wereconducted.ResultsNilotinib lipid suspensions did not show a bioavail-ability increase compared to an aqueous suspension. The bio-availability was lower for triglyceride suspensions, relative toboth monoglyceride and an aqueous suspension. The longchain monoglyceride displayed a significantly higher bioavail-ability relative to triglycerides.In vitrolipolysis results suggestedentrapment of nilotinib crystals within poorly dispersible tri-glycerides, leading to slower nilotinib release and absorption.This was further supported by higher wettability of nilotinibby lipids.ConclusionMonoglycerides improved oral bioavailability ofnilotinib in rats, relative to triglycerides. For‘brick dust’drugsformulated as lipid suspensions, poorly dispersible formula-tions may delay the release of drug crystals from the formula-tion leading to reduced absorption.en_US
dc.description.urihttps://www.ncbi.nlm.nih.gov/pubmed/30796596en_US
dc.identifier.doi10.1007/s11095-019-2590-y
dc.identifier.issn0724-8741
dc.identifier.issn1573-904X
dc.identifier.urihttps://irf.fhnw.ch/handle/11654/30424
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofPharmaceutical Researchen_US
dc.subjectbio-enabling formulationen_US
dc.subjectbrick dusten_US
dc.subjectlipid suspensionen_US
dc.subjectlipid based formulationen_US
dc.subjectnilotiniben_US
dc.titleNew Insights into Using Lipid Based Suspensions for 'Brick Dust' Molecules: Case Study of Nilotiniben_US
dc.type01A - Beitrag in wissenschaftlicher Zeitschrift
dc.volume36en_US
dspace.entity.typePublication
fhnw.InventedHereYesen_US
fhnw.IsStudentsWorknoen_US
fhnw.PublishedSwitzerlandYesen_US
fhnw.ReviewTypeAnonymous ex ante peer review of a complete publicationen_US
fhnw.affiliation.hochschuleHochschule für Life Sciences FHNWde_CH
fhnw.affiliation.institutInstitut für Pharma Technologyde_CH
fhnw.publicationOnlineJaen_US
fhnw.publicationStatePublisheden_US
relation.isAuthorOfPublication68819448-8611-488b-87bc-1b1cf9a6a1b4
relation.isAuthorOfPublication.latestForDiscovery68819448-8611-488b-87bc-1b1cf9a6a1b4
Dateien